squalamine phosphate (ENT-01)

From Aaushi

Jump to navigation Jump to search

^[1]

Indications

treatment of constipation in patients with Parkinson's disease (investigational)
- may improve cognition in patients with Parkinson's disease^[1]

Dosage

250 mg PO QD
- starting dose may be lower, optimal dose may be higher

Adverse effects

nausea (34%)
diarrhea (19%)

Mechanism of action

inhibits formation of alpha-synuclein in enteric neurons

More general terms

References

↑ ^1.0 ^1.1 Camilleri M et al. Oral ENT-01 targets enteric neurons to treat constipation in Parkinson disease: A randomized controlled trial. Ann Intern Med 2022 Nov 8; [e-pub]. PMID: https://www.ncbi.nlm.nih.gov/pubmed/36343348 https://www.acpjournals.org/doi/10.7326/M22-1438

Database

PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=86653613

Retrieved from "https://aaushi.info/w/index.php?title=A57815&oldid=1137502"

↑ Back to top